Richard Hamilton

Authored Content

A new Avalere analysis examines the prevalence of utilization management (UM) in the commercial market from 2014 to 2020, focusing on drugs treating cancer, autoimmune diseases, and a range of other chronic conditions.

Consumers ages 50–64 could see higher exchange premiums starting in 2023 without extension of ARPA subsidies.